These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 24899509)

  • 1. Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer.
    Gao J; Azmi AS; Aboukameel A; Kauffman M; Shacham S; Abou-Samra AB; Mohammad RM
    Oncotarget; 2014 Jun; 5(11):3444-54. PubMed ID: 24899509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
    Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M; Croce CM; Marcucci G; Garzon R
    Blood; 2012 Aug; 120(9):1765-73. PubMed ID: 22677130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
    Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
    Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
    Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
    Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
    Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
    J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
    Etchin J; Sun Q; Kentsis A; Farmer A; Zhang ZC; Sanda T; Mansour MR; Barcelo C; McCauley D; Kauffman M; Shacham S; Christie AL; Kung AL; Rodig SJ; Chook YM; Look AT
    Leukemia; 2013 Jan; 27(1):66-74. PubMed ID: 22847027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.
    Boons E; Vanstreels E; Jacquemyn M; Nogueira TC; Neggers JE; Vercruysse T; van den Oord J; Tamir S; Shacham S; Landesman Y; Snoeck R; Pannecouque C; Andrei G; Daelemans D
    EBioMedicine; 2015 Sep; 2(9):1102-13. PubMed ID: 26501108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
    Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
    Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.
    Azmi AS; Muqbil I; Wu J; Aboukameel A; Senapedis W; Baloglu E; Bollig-Fischer A; Dyson G; Kauffman M; Landesman Y; Shacham S; Philip PA; Mohammad RM
    Sci Rep; 2015 Nov; 5():16077. PubMed ID: 26536918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts.
    Wang S; Han X; Wang J; Yao J; Shi Y
    PLoS One; 2014; 9(3):e89848. PubMed ID: 24595136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
    Etchin J; Sanda T; Mansour MR; Kentsis A; Montero J; Le BT; Christie AL; McCauley D; Rodig SJ; Kauffman M; Shacham S; Stone R; Letai A; Kung AL; Thomas Look A
    Br J Haematol; 2013 Apr; 161(1):117-27. PubMed ID: 23373539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
    Yang J; Bill MA; Young GS; La Perle K; Landesman Y; Shacham S; Kauffman M; Senapedis W; Kashyap T; Saint-Martin JR; Kendra K; Lesinski GB
    PLoS One; 2014; 9(7):e102983. PubMed ID: 25057921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
    Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.
    Azmi AS; Khan HY; Muqbil I; Aboukameel A; Neggers JE; Daelemans D; Mahipal A; Dyson G; Kamgar M; Al-Hallak MN; Tesfaye A; Kim S; Shidham V; M Mohammad R; Philip PA
    Clin Cancer Res; 2020 Mar; 26(6):1338-1348. PubMed ID: 31831564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer.
    Ji S; Qin Y; Shi S; Liu X; Hu H; Zhou H; Gao J; Zhang B; Xu W; Liu J; Liang D; Liu L; Liu C; Long J; Zhou H; Chiao PJ; Xu J; Ni Q; Gao D; Yu X
    Cell Res; 2015 May; 25(5):561-73. PubMed ID: 25753158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HnRNPK/miR-223/FBXW7 feedback cascade promotes pancreatic cancer cell growth and invasion.
    He D; Huang C; Zhou Q; Liu D; Xiong L; Xiang H; Ma G; Zhang Z
    Oncotarget; 2017 Mar; 8(12):20165-20178. PubMed ID: 28423622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion.
    Jin X; Yang C; Fan P; Xiao J; Zhang W; Zhan S; Liu T; Wang D; Wu H
    J Biol Chem; 2017 Apr; 292(15):6269-6280. PubMed ID: 28242758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth.
    Inoue H; Kauffman M; Shacham S; Landesman Y; Yang J; Evans CP; Weiss RH
    J Urol; 2013 Jun; 189(6):2317-26. PubMed ID: 23079374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
    Sexton R; Mahdi Z; Chaudhury R; Beydoun R; Aboukameel A; Khan HY; Baloglu E; Senapedis W; Landesman Y; Tesfaye A; Kim S; Philip PA; Azmi AS
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.